Home » Healthcare » Pharmaceuticals » Glioblastoma Multiforme Market

Glioblastoma Multiforme Market By Surgery (Radiation Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Tumor Treating Fields (TTF) Therapy, Supportive Care); By Drug Class (Chemotherapy Agents: Temozolomide, Carmustine, Lomustine, Others); By Immunotherapy Agents (Checkpoint Inhibitors, Vaccines, Others); By End-User (Hospitals, Cancer Research Institutes, Ambulatory Surgical Centers, Others); By Targeted Therapy Agents (Bevacizumab, Erlotinib, Others); By Clinical Trial Phase (Phase I, Phase II, Phase III, Phase IV); By Diagnostic Tools (MRI, CT Scan, Biopsy, Others); By Region – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Price: $4999

Published: | Report ID: 6632 | Report Format : PDF
REPORT ATTRIBUTE DETAILS
Historical Period  2019-2022
Base Year  2023
Forecast Period  2024-2032
Glioblastoma Multiforme Market Size 2023  USD 2512.5 Million
Glioblastoma Multiforme Market, CAGR  9.2%
Glioblastoma Multiforme Market Size 2032  USD 5547.7 Million

Market Insights

  • The global demand for glioblastoma multiforme was valued at USD 2512.5 Million in 2023 and is expected to reach USD 5547.7 Million in 2032, growing at a CAGR of 9.2% between 2024 and 2032.
  • Radiation therapy is the market leader by surgery, accounting for more than 20% of total value in 2023, while chemotherapy is predicted to increase substantially over the forecast time frame.
  • The hospital end-user dominates the global need for glioblastoma multiforme, accounting for more than 30% in 2023, and is anticipated to grow at an elevated CAGR.
  • Over the projected period, the biopsy segment will likely expand at the highest rate, while the MRI diagnostic tools category dominated the market in 2023 with a 28% share.
  • The temozolomide dominated the market with 32% of the total revenue share by drug class category. In contrast, the carmustine will expand fastest in the projected period.
  • North America majorly contributes to the growth of the glioblastoma multiforme industry, accounting for more than one-third of the total in 2023, while Asia Pacific and Europe account for just under 55%. Europe accounted for more than 22% of the global market in 2023.
  • Global incidence of brain and central nervous system (CNS) malignancies cases reached 308,102 in 2020, with 251,329 fatalities, according to the Global Cancer Observatory. Glioblastoma multiforme is the most common type of malignant tumor, accounting for nearly 54% of gliomas and 16% of all primary brain malignancies.
  • Adults are more likely than children to develop glioblastoma multiforme, and the risk increases with age. The growing evidence suggests targeted therapy and healing interventions will likely propel the glioblastoma multiforme market size in the coming years.

Glioblastoma Multiforme Market

Design Element 2

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

CTA Design Element 3

Executive Summary

Market Definition

Glioblastoma multiforme, or grade IV astrocytoma, is an aggressive grade IV brain tumor that rapidly expands within brain cells and can infect adjacent cells. It exerts an immense amount of strain on the brain due to its fast cell deterioration, which causes excruciating headaches and seizures. Although the specific causation of the diseases is unknown, various factors, including uncommon inherited disorders like Turcot syndrome, are considered to be involved. It is one of the most fatal kinds of brain cancer and is treatment-resistant, with patients having an exceptionally limited survival period after diagnosis. Surgical resection, radiation therapy, immunotherapy, chemotherapy, and TTF therapy are the current treatment options for this disease.

Market Overview

The global glioblastoma multiforme market has witnessed consistent growth over recent years and is set to grow at a CAGR of 9.2% between 2024 and 2032. The market was valued at USD 2512.5 million in 2023 and is estimated to reach USD 5547.7 million in 2032.

According to WHO 2021, glioblastoma multiforme (GBM) is now classified as a diffuse astrocytic glioma without alterations in the histone H3 or IDH genes. It is the most prevalent primary brain tumor in humans. GBM, like other astrocytomas, is caused by astrocytes, which are non-neuronal glial cells that offer structural and biochemical support to the brain’s neuronal network. GBM remains a disease with among the most unmet demands in oncology, with patients having a median overall survival (OS) of one to two years. The inability of drugs to pass through the blood-brain barrier (BBB) is the primary reason for the lack of therapeutics.

The rising prevalence of glioblastoma multiforme cases and the scarcity of existing treatment choices have created a compelling demand for novel and effective medicines, supporting market expansion. Technological and scientific developments in medicine have helped to provide new approaches to treating glioblastoma multiforme. The market has shifted towards personalized medical techniques, targeting tumor treating fields (TTF) therapy and immunotherapy. Targeted therapies, such as tyrosine kinase inhibitors and monoclonal antibodies, seek to disrupt specific biochemical processes implicated in the progression of glioblastoma multiforme. Immunotherapies, which include immune checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell treatment, use the immune system to identify and eliminate cancer cells. These developments have substantially enhanced treatment outcomes, accelerating the expansion of the glioblastoma multiforme market.

Segmentation by Surgery

  • Radiation therapy is the leading surgery segment and held over 20% share in value in 2023. It is a crucial treatment modality for glioblastoma multiforme, delivering focused radiation to target cancer cells while minimizing damage to surrounding healthy tissue.
  • The chemotherapy category is likely to experience a large market CAGR, mainly due to the ongoing development of innovative chemotherapeutic agents and combination therapies to improve treatment outcomes for glioblastoma patients.

Segmentation by Drug Class

  • Temozolomide dominates the global demand for glioblastoma multiforme, with a massive market share of over 32% in 2023, owing to its established efficacy and tolerable side effects profile.
  • The carmustine and lomustine drug class segments fulfill the remaining glioblastoma multiforme market demands, providing additional options for patients who may not respond optimally to temozolomide-based regimens.

Segmentation by End-User

  • The cancer research institutes category is predicted to have the greatest CAGR. These institutes serve essential duties in glioblastoma research, undertaking preclinical investigations, clinical trials, and translational research to identify new medicines and improve treatment regimens.
  • The hospitals segment is leading the market share with over 30% share in 2023. Hospitals serve as the primary treatment centers for glioblastoma patients, offering comprehensive diagnostic, therapeutic, and supportive care services under one roof.

Segmentation by Immunotherapy Agents

  • The vaccines segment is anticipated to register the largest CAGR, fueled by advancements in cancer immunotherapy research and the development of personalized vaccines targeting glioblastoma-specific antigens.
  • With a market share of nearly 40% in 2023, the checkpoint inhibitors category is currently in the lead. Checkpoint inhibitors have revolutionized cancer treatment by blocking immune checkpoints, unleashing the immune system to attack tumor cells, and are increasingly being explored for glioblastoma therapy.

Segmentation by Targeted Therapy Agents

  • Bevacizumab dominates the market revenue share in targeted therapy agents, accounting for more than 38% in 2023, owing to its efficacy in glioblastoma treatment by targeting tumor angiogenesis.
  • The rest of the market demand for glioblastoma multiforme comes from the erlotinib. Erlotinib, an epidermal growth factor receptor (EGFR) inhibitor, is another targeted therapy option for treating glioblastoma, particularly in EGFR-overexpressing tumors.

Segmentation by Clinical Trial Phase

  • The clinical trial phase I segment leads the global market share, representing the early stages of medication development and testing. Phase I trials assess the safety, dose, and potential side effects of investigational medications in a small number of patients, establishing the framework for future clinical development.
  • Phase III is the fastest-growing clinical trial category, primarily due to developments in clinical research and drug efficacy evaluation. Phase III trials evaluate the safety and efficacy of new medicines compared to standard of care or placebo and are important for regulatory approvals and market access.

Segmentation by Diagnostic Tools

  • MRI is the most popular diagnostic instrument category, accounting for 34% of the market in 2023 due to its superior precision and non-invasive nature. Magnetic resonance imaging (MRI) is essential in glioblastoma diagnosis, providing comprehensive anatomical pictures that assist in tumor localization, characterization, and treatment planning.
  • CT scans and biopsies also contribute extensively to the market, with biopsy experiencing the largest CAGR. Computed tomography (CT) scans offer complementary imaging information, particularly for assessing bone involvement and detecting tumor-related complications. Biopsy remains the gold standard for definitive glioblastoma diagnosis, allowing for histopathological examination and molecular profiling of tumor tissue.

Segmentation by Region

  • North America continues to lead the expansion of the glioblastoma multiforme industry, with over one-third share in 2023, supported by robust healthcare infrastructure, research funding, and clinical trial activity focused on glioblastoma treatment innovations.
  • Europe and Asia Pacific, collectively accounting for just under 55% of the share in 2023, represent key market opportunities owing to increasing disease incidence, growing awareness, and efforts to improve access to innovative therapies.
  • The rest of the world, encompassing regions such as Latin America, the Middle East, and Africa, presents the untapped potential for glioblastoma multiforme market expansion, attributed to the evolving healthcare systems and unmet medical needs.

The growing global burden of brain disorders, strong R&D investments from key competitors, and an aging population are all pushing the rise of the glioblastoma multiforme treatment market revenue.

North America dominated the global glioblastoma multiforme treatment market in 2023, owing to increased financial support and patient awareness programs. Government support for healthcare development, widespread awareness of brain illnesses and tumors, readily available access to high-quality medical facilities, and favorable reimbursement policies support the regional market’s growth. In February 2022, the American Society of Clinical Oncology (ASCO) predicted that 25,050 adults in the U.S. (14,170 men and 10,880 women) would receive a primary malignant tumor diagnosis in their brain or spinal cord. Also, 85% to 90% of all primary CNS tumors are brain tumors. In addition, approximately 4,170 children under the age of 15 have been identified with a brain or CNS tumor in the United States in 2022.

Asia Pacific will likely have the fastest glioblastoma multiforme market development rate of 10.2% over the projected time frame, owing to the introduction of generic temozolomide, an improving economy, a growing geriatric population, and increased healthcare sector investments. The prevalence of significant unmet needs in the region, rising awareness of GBM, and a rich product pipeline (molecules that can cross the blood-brain barrier) are all critical contributors to market expansion.

Various initiatives launched by governments and non-governmental organizations worldwide to spread awareness by educating people living with glioblastoma multiforme and raising funds for R&D trials and treatment are anticipated to propel the growth of the GBM treatment market throughout the estimated period. For example, Ping Mobile, a smartphone messaging platform, recently introduced a mobile campaign to raise brain cancer awareness. This helps to increase awareness of glioblastoma multiforme and encourages individuals to donate money to glioblastoma multiforme research initiatives.

Organizations such as the National Brain Tumour Society, the Brain Tumour Foundation of Canada, and the Cure Brain Cancer Foundation also participate in various awareness efforts to raise general awareness about the condition. In the United Kingdom, March is Brain Tumour Awareness Month, founded by Brain Tumour Research member charities. The campaign’s primary goal is to raise awareness about the shortage of financing for brain tumor research and to assist people in understanding brain tumors and their treatment. Furthermore, Novocure participated in numerous events to spread comprehension about glioblastoma multiforme during Brain Tumour Awareness Month.

Key Highlights of the Report

The global glioblastoma multiforme market is segmented by surgery, drug class, immunotherapy agents, targeted therapy agents, end-user, clinical trial phase, diagnostic tools, and region. Radiation therapy emerges as a leading treatment modality, supported by its effectiveness in managing glioblastoma multiforme symptoms. Temozolomide commands significant market demand within drug classes, while the cancer research institutes category is anticipated to witness the highest growth rate among end-users. Moreover, the MRI stands out as the dominant diagnostic tool category, facilitating accurate disease detection and monitoring.

The rising prevalence of oncological illnesses and a growing elderly population worldwide are among the primary factors propelling the market’s growth. In addition, developing novel treatment approaches that counteract the resistant qualities of glioma stem cells favorably impacts market developments. Moreover, increased R&D operations in the fields of molecular biotechnology and gene therapies for cancer and associated diseases have accelerated the discovery of numerous biological treatments. These drugs help to reduce the negative effects of established treatment modalities, leading to more patient acceptability. Additionally, global government measures to enhance healthcare infrastructure and growing awareness of the availability of multiple drugs are anticipated to improve the market outlook for glioblastoma multiforme. However, a higher failure rate has already been recorded for late-stage GBM trials, which may impact pipeline forecasts and restrict market expansion.

North America has the largest global glioblastoma multiforme market revenue share. This region features a high presence of major pharmaceutical companies, excellent healthcare facilities, and an intense focus on R&D. North America, notably the United States, has made huge investments in glioblastoma multiforme treatments, clinical trials, and research. Moreover, the region has a greater incidence of glioblastoma multiforme treatment cases, increasing the necessity for appropriate treatment choices. The GMB incidence rate in the United States is 3.19 per 100,000 people, further projected to push regional market size.

Asia-Pacific is the fastest-growing region in the global treatment market for glioblastoma multiforme. This region has a huge population and is seeing an increase in glioblastoma multiforme patients. Furthermore, China, India, and Japan consistently invest in healthcare infrastructure expansion and research projects. Growing awareness of glioblastoma multiforme treatment and the availability of proficient treatment alternatives are boosting revenue growth in this region.

What Are The Main Drivers Of The Global Glioblastoma Multiforme Market?

The main drivers of the global glioblastoma multiforme market include advancements in treatment options, such as targeted therapy agents like bevacizumab, and the increasing prevalence of glioblastoma cases worldwide. Besides, growing investments in R&D for innovative therapies and diagnostic tools further contribute to market growth.

What Are The Major Challenges Faced By The Global Glioblastoma Multiforme Market?

The high cost of treatment approaches will undoubtedly limit market expansion. Several treatments involved in this, like chemotherapy, targeted therapy, and immunotherapy, are expensive, which hampers market growth. A lack of skilled experts experienced in the disease’s treatment procedures also impedes the global glioblastoma treatment market’s development over the forecast time frame.

What Are The Growth Opportunities In The Global Glioblastoma Multiforme Market?

Techniques such as a genetic mutation in specific tumor cells are becoming more prominent in treating glioblastoma multiforme, contributing to market expansion. For example, certain tumors contain mutations in the epidermal growth factor receptor (EGFR) gene, which can be targeted with medications like gefitinib and erlotinib. Furthermore, increased drug approvals for managing glioblastoma multiforme contribute to market developments in the treatment sector. For example, in June 2022, the FDA authorized the combination of dabrafenib and trametinib drugs. These drugs are targeted therapeutics that fight cancer cells with BRAF mutations.

Market Drivers

Several factors contribute to the global glioblastoma multiforme market growth. The primary factors propelling the global glioblastoma multiforme market are as follows:

Increased Cases Of Brain Disorders

The increasing frequency of neurological disorders is projected to expand the glioblastoma multiforme (GBM) treatment market in the coming years. Brain disorders are abnormalities in the brain and the nerves that run throughout the human body and spinal cord. The rising prevalence of brain diseases such as glioblastoma multiforme (GBM) is caused by several factors, including an aging population, weakened immune systems, overdiagnosis, ionizing radiation, air pollution, and others, necessitating the treatment of brain disorders to improve well-being.

The American Association of Neurological Surgeons reports that as of June 2021, 3.21 per 100,000 adults over 60 had glioblastoma, accounting for 47.7% of all cases and affecting men at a higher rate than women.

Market Restraints

The global glioblastoma multiforme market faces some challenges that limit its expansion. These consist of the following:

High Treatment Costs

The cost of glioblastoma multiforme treatment is a financial hardship for individuals, owing to the costs connected with radiation therapy, surgery, chemotherapy, and supportive care. Higher treatment costs can limit patient access to modern medicines and impact treatment affordability. In addition, reimbursement regulations significantly impact patient access to these medicines, affecting market expansion.

Opportunities

The global glioblastoma multiforme market presents tremendous potential opportunities. These consist of the following:

Increasing R&D Activities

An increase in R&D initiatives to develop novel targeted and immunotherapeutic treatments is predicted to result in a higher survival rate and a better prognosis for glioblastoma multiforme patients. Organizations, including Denovo Biopharma, Samsung Bioepis, Kazia Therapeutics Limited, Laminar Pharmaceuticals, and Bristol Myers Squibb, actively develop innovative therapies for treating glioblastoma multiforme.

Leading players in the glioblastoma multiforme treatment market are working on new forms of radiopharmaceutical therapy to address the demand for enhanced and tailored therapeutic options. Radiopharmaceutical treatment uses radioactive chemicals to cure diseases by administering targeted radiation to certain organs or tissues. It is frequently utilized to eradicate cancer cells during cancer treatment. For example, in February 2022, Theragnostics, a UK-based supplier of diagnostic molecular imaging and molecular radiotherapy products, announced that the UK MHRA had awarded the new I-123 PARPi (THG-009) therapy an innovation passport to treat primary and persistent glioblastoma multiforme.

Competitive Landscape

Design Element 2

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

CTA Design Element 3

Key Players

The glioblastoma multiforme treatment market is highly concentrated, owing to the presence of leading players operating both internationally and regionally. The following are a few of the most prominent market players and their market shares:

  • Merck & Co. Inc
  • Amgen Inc
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc
  • Teva Pharmaceutical Industries Ltd
  • Sun Pharmaceutical Industries Ltd
  • Arbor Pharmaceuticals LLC
  • Amneal Pharmaceuticals
  • Karyopharm Therapeutics Inc
  • Others

These major players are expanding their manufacturing capabilities, strengthening their product portfolios, and creating competitive distinctiveness through partnerships, licensing, mergers, and acquisitions. Key companies in the GBM treatment market are making continuous R&D investments to develop novel therapies and acquire a competitive advantage.

In June 2023, Chimeric Therapeutics started a Phase IB clinical study of CHM 1101 (CLXT CAR T) stem cell therapy to treat patients with recurrent or progressing glioblastoma multiforme (GBM). The purpose of this study is to examine the efficacy and safety of CHM 1101 in patients with a highly life-threatening kind of primary brain cancer.

In March 2023, Merck & Co. Inc. announced that the FDA had authorized Keytruda (pembrolizumab) combined with temozolomide for adjuvant therapy of people with recently diagnosed, high-risk glioblastoma multiforme.

In January 2022, ITM Isotope Technologies Munich SE, a German pharma company, signed an agreement to collaborate with Helmholtz Zentrum München, the German Research Centre for Environmental Health, on the clinical development of radiopharmaceutical therapy for the intervention of glioblastoma multiforme.

In April 2021, Lineage Cell Therapeutics signed a licensing deal with Immunomic Therapeutics to develop allogeneic VAC, a cancer immunological platform, for treating glioblastoma multiforme. Lineage will get an upfront payment of USD 2 million, followed by commercial milestone payments of USD 67 million, according to the terms of the agreement.

Summary of Key Findings

  • The global market for glioblastoma multiforme has grown drastically in recent years, owing to an increase in the number of glioblastoma multiforme treatment cases across the globe and a growing preference for effective therapeutic options.
  • The market is segmented by surgery, drug class, immunotherapy agents, targeted therapy agents, end-user, clinical trial phase, diagnostic tools, and region.
  • Radiation therapy emerges as a leading surgery segment, while the temozolomide drug class category dominates the global market demand for GBM treatments.
  • Checkpoint inhibitors hold a substantial market share among immunotherapy agents, with vaccines anticipated to register the largest CAGR.
  • However, challenges such as higher treatment costs, limited efficacy of existing therapies, and complex regulatory pathways pose substantial barriers to market expansion and innovation in the GBM space.

Future Outlook

  • Increasing emphasis on early detection and diagnosis of GBM through advancements in imaging techniques, molecular biomarkers, and liquid biopsy approaches is driving research efforts and shaping the future of GBM management.
  • The emerging market demands for a personalized therapeutic method to control glioblastoma multiforme will increase due to tumor heterogeneity and diversity in patient-to-patient treatment techniques. The approval of novel treatments will likely extend the survival rates of patients with glioblastoma multiforme.

How CXOs Can Benefit from the Credence Research Glioblastoma Multiforme Market Report

The Credence Research Glioblastoma Multiforme Market Report provides CXOs with a comprehensive overview of the market, including:

  • Market Size and Growth Forecast: The report provides detailed estimates of the global glioblastoma multiforme market size, segmented by surgery, drug class, immunotherapy agents, targeted therapy agents, end-user, clinical trial phase, diagnostic tools, and region. It also includes forecasts for the market through 2032 based on key trends and drivers in the glioblastoma treatment landscape.
  • Market Segmentation: The report segments the glioblastoma multiforme market by surgery, drug class, immunotherapy agents, targeted therapy agents, end-user, clinical trial phase, diagnostic tools, and region. This segmentation enables CXOs to identify specific areas of opportunity and tailor their strategies accordingly.
  • Competitive Landscape: CXOs can assess the competitive landscape of the glioblastoma multiforme market through profiles of key players, their strategies, product offerings, and financial performance. For instance, it highlights the competitive strategies leading pharmaceutical companies employ in launching innovative targeted therapy agents to address unmet medical needs in glioblastoma treatment.
  • Key Trends and Drivers: The report identifies and analyzes key trends and drivers shaping the glioblastoma multiforme market, such as advances in surgical techniques, emerging drug classes, and increasing adoption of immunotherapy and targeted therapy agents. CXOs can leverage these insights to make informed decisions about investments and strategic initiatives.

CXOs can use the insights from the Credence Research Glioblastoma Multiforme Market Report to:

  • Identify Growth Opportunities: The report identifies growth opportunities, such as expanding into emerging regions with high incidence rates of glioblastoma or investing in research collaborations to develop personalized treatment approaches. For example, CXOs can explore collaboration opportunities with academic research institutions to accelerate the development of novel immunotherapy agents.
  • Make Informed Investment Decisions: With insights from the report, CXOs can make informed investment decisions, develop competitive strategies, and track market developments to stay ahead of the competition. For example, understanding the market dynamics of different drug classes can help pharmaceutical companies prioritize their pipeline investments and commercialization strategies.
  • Develop Competitive Strategies: The report can help CXOs develop competitive strategies for glioblastoma multiforme businesses. For example, the report identifies the key strategies that glioblastoma multiforme treatment providers use to differentiate themselves from their competitors.
  • Track Market Developments: The report provides insights into the latest developments and innovations in the glioblastoma multiforme market, helping CXOs anticipate changes and adapt their strategies accordingly. For instance, staying ahead of emerging diagnostic tools such as MRI and biopsy techniques can inform decisions regarding integrating new technologies into clinical practice.

Overall, the Credence Research Glioblastoma Multiforme Market Report is a valuable resource for CXOs looking to gain a deeper understanding of the market and identify growth opportunities.

Segmentation

By Surgery

  • Radiation Therapy
  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy
  • Tumor Treating Fields (TTF) Therapy
  • Supportive Care

By Drug Class

  • Chemotherapy Agents:
  • Temozolomide
  • Carmustine
  • Lomustine
  • Others

By Immunotherapy Agents

  • Checkpoint Inhibitors
  • Vaccines
  • Others

By End-User

  • Hospitals
  • Cancer Research Institutes
  • Ambulatory Surgical Centers
  • Others

By Targeted Therapy Agents

  • Bevacizumab
  • Erlotinib
  • Others

By Clinical Trial Phase

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

By Diagnostic Tools

  • MRI
  • CT Scan
  • Biopsy
  • Others

By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East and Africa

Table of Content
1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Market Introduction
2. Executive Summary
2.1. Market Snapshot: Global Glioblastoma Multiforme Market
2.1.1. Global Glioblastoma Multiforme Market, By Surgery
2.1.2. Global Glioblastoma Multiforme Market, By End-User
2.1.3. Global Glioblastoma Multiforme Market, By Drug Class
2.1.4. Global Glioblastoma Multiforme Market, By Immunotherapy Agents
2.1.5. Global Glioblastoma Multiforme Market, By Targeted Therapy Agents
2.1.6. Global Glioblastoma Multiforme Market, By Clinical Trial Phase
2.1.7. Global Glioblastoma Multiforme Market, By Diagnostic Tools
2.1.8. Global Glioblastoma Multiforme Market, By Region
2.2. Insights from Primary Respondents
3. Market Dynamics & Factors Analysis
3.1. Introduction
3.1.1. Global Glioblastoma Multiforme Market Value, 2019-2032, (US$ Mn)
3.1.2. Y-o-Y Growth Trend Analysis
3.2. Market Dynamics
3.2.1. Glioblastoma Multiforme Market Drivers
3.2.2. Glioblastoma Multiforme Market Restraints
3.2.3. Glioblastoma Multiforme Market Opportunities
3.2.4. Major Glioblastoma Multiforme Industry Challenges
3.3. Growth and Development Patterns
3.4. Investment Feasibility Analysis
3.5. Market Opportunity Analysis
3.5.1. Surgery
3.5.2. End-User
3.5.3. Drug Class
3.5.4. Immunotherapy Agents
3.5.5. Targeted Therapy Agents
3.5.6. Clinical Trial Phase
3.5.7. Diagnostic Tools
3.5.8. Geography
4. Market Competitive Landscape Analysis
4.1. Company Market Share Analysis, 2023
4.1.1. Global Glioblastoma Multiforme Market: Company Market Share, Value 2023
4.1.2. Global Glioblastoma Multiforme Market: Top 6 Company Market Share, Value 2023
4.1.3. Global Glioblastoma Multiforme Market: Top 3 Company Market Share, Value 2023
4.2. Global Glioblastoma Multiforme Market: Company Revenue Share Analysis, 2023
4.3. Company Assessment Metrics, 2023
4.3.1. Stars
4.3.2. Emerging Leaders
4.3.3. Pervasive Players
4.3.4. Participants
4.4. Startups/ SMEs Assessment Metrics, 2023
4.4.1. Progressive Companies
4.4.2. Responsive Companies
4.4.3. Dynamic Companies
4.4.4. Starting Blocks
4.5. Strategic Development
4.5.1. Acquisition and Mergers
4.5.2. New Product Launch
4.5.3. Regional Expansion
4.5.4. Partnerships
4.6. Key Player Product Matrix
4.7. Potential for New Players in the Global Glioblastoma Multiforme Market
5. Premium Insights
5.1. STAR (Situation, Task, Action, Results) Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Bargaining Power of Buyers/Consumers
5.2.3. Bargaining Power of Suppliers
5.2.4. Threat of Substitute Types
5.2.5. Intensity of Competitive Rivalry
5.3. PESTEL Analysis
5.3.1. Political Factors
5.3.2. Economic Factors
5.3.3. Social Factors
5.3.4. Technological Factors
5.3.5. Environmental Factors
5.3.6. Legal Factors
5.4. Key Market Trends
5.4.1. Demand Side Trends
5.4.2. Supply Side Trends
5.5. Value Chain Analysis
5.6. Technology Analysis
5.6.1. Research and development in the global market
5.6.2. Patent Analysis
5.6.3. Emerging technologies and their potential disruption to the market
5.7. Consumer Behaviour Analysis
5.7.1. Consumer Preferences and Expectations
5.7.2. Factors Influencing Consumer Buying Decisions
5.7.2.1. North America
5.7.2.2. Europe
5.7.2.3. Asia Pacific
5.7.2.4. Latin America
5.7.2.5. Middle East and Africa
5.7.3. Consumer Pain Points
5.8. Analysis and Recommendations
5.9. Adjacent Market Analysis
6. Market Positioning of Key Players, 2023
6.1. Company market share of key players, 2023
6.2. Competitive Benchmarking
6.3. Market Positioning of Key Vendors
6.4. Geographical Presence Analysis
6.5. Major Strategies Adopted by Key Players
6.5.1. Key Strategies Analysis
6.5.2. Mergers and Acquisitions
6.5.3. Partnerships
6.5.4. Product Launch
6.5.5. Geographical Expansion
6.5.6. Others
7. Impact Analysis of COVID 19 and Russia – Ukraine War on Glioblastoma Multiforme Market
7.1. Ukraine-Russia War Impact
7.1.1. Uncertainty and Economic Instability
7.1.2. Supply chain disruptions
7.1.3. Regional market shifts
7.1.4. Shift in government priorities
7.2. COVID-19 Impact Analysis
7.2.1. Supply Chain Disruptions
7.2.2. Demand Fluctuations
7.2.3. Shift in Product Mix
7.2.4. Reduced Industrial Activity
7.2.5. Regional Impact Analysis
7.2.5.1. North America
7.2.5.2. Europe
7.2.5.3. Asia Pacific
7.2.5.4. Latin America
7.2.5.5. Middle East and Africa
8. Global Glioblastoma Multiforme Market, By Surgery
8.1. Global Glioblastoma Multiforme Market Overview, by Surgery
8.1.1. Global Glioblastoma Multiforme Market Revenue Share, By Surgery, 2023 Vs 2032 (in %)
8.2. Radiation Therapy
8.2.1. Global Glioblastoma Multiforme Market, By Radiation Therapy, By Region, 2019-2032 (US$ Mn)
8.2.2. Market Dynamics for Radiation Therapy
8.2.2.1. Drivers
8.2.2.2. Restraints
8.2.2.3. Opportunities
8.2.2.4. Trends
8.3. Chemotherapy
8.3.1. Global Glioblastoma Multiforme Market, By Chemotherapy, By Region, 2019-2032 (US$ Mn)
8.3.2. Market Dynamics for Chemotherapy
8.3.2.1. Drivers
8.3.2.2. Restraints
8.3.2.3. Opportunities
8.3.2.4. Trends
8.4. Immunotherapy
8.4.1. Global Glioblastoma Multiforme Market, By Immunotherapy, By Region, 2019-2032 (US$ Mn)
8.4.2. Market Dynamics for Immunotherapy
8.4.2.1. Drivers
8.4.2.2. Restraints
8.4.2.3. Opportunities
8.4.2.4. Trends
8.5. Targeted Therapy
8.5.1. Global Glioblastoma Multiforme Market, By Targeted Therapy, By Region, 2019-2032 (US$ Mn)
8.5.2. Market Dynamics for Targeted Therapy
8.5.2.1. Drivers
8.5.2.2. Restraints
8.5.2.3. Opportunities
8.5.2.4. Trends
8.6. Tumor Treating Fields (TTF) Therapy
8.6.1. Global Glioblastoma Multiforme Market, By Tumor Treating Fields (TTF) Therapy, By Region, 2019-2032 (US$ Mn)
8.6.2. Market Dynamics for Tumor Treating Fields (TTF) Therapy
8.6.2.1. Drivers
8.6.2.2. Restraints
8.6.2.3. Opportunities
8.6.2.4. Trends
8.7. Supportive Care
8.7.1. Global Glioblastoma Multiforme Market, By Supportive Care, By Region, 2019-2032 (US$ Mn)
8.7.2. Market Dynamics for Supportive Care
8.7.2.1. Drivers
8.7.2.2. Restraints
8.7.2.3. Opportunities
8.7.2.4. Trends
9. Global Glioblastoma Multiforme Market, By End-User
9.1. Global Glioblastoma Multiforme Market Overview, by End-User
9.1.1. Global Glioblastoma Multiforme Market Revenue Share, By End-User, 2023 Vs 2032 (in %)
9.2. Hospitals
9.2.1. Global Glioblastoma Multiforme Market, By Hospitals, By Region, 2019-2032 (US$ Mn)
9.2.2. Market Dynamics for Hospitals
9.2.2.1. Drivers
9.2.2.2. Restraints
9.2.2.3. Opportunities
9.2.2.4. Trends
9.3. Cancer Research Institutes
9.3.1. Global Glioblastoma Multiforme Market, By Cancer Research Institutes, By Region, 2019-2032 (US$ Mn)
9.3.2. Market Dynamics for Cancer Research Institutes
9.3.2.1. Drivers
9.3.2.2. Restraints
9.3.2.3. Opportunities
9.3.2.4. Trends
9.4. Ambulatory Surgical Centers
9.4.1. Global Glioblastoma Multiforme Market, By Ambulatory Surgical Centers, By Region, 2019-2032 (US$ Mn)
9.4.2. Market Dynamics for Ambulatory Surgical Centers
9.4.2.1. Drivers
9.4.2.2. Restraints
9.4.2.3. Opportunities
9.4.2.4. Trends
9.5. Others
9.5.1. Global Glioblastoma Multiforme Market, By Others, By Region, 2019-2032 (US$ Mn)
9.5.2. Market Dynamics for Others
9.5.2.1. Drivers
9.5.2.2. Restraints
9.5.2.3. Opportunities
9.5.2.4. Trends
10. Global Glioblastoma Multiforme Market, By Drug Class
10.1. Global Glioblastoma Multiforme Market Overview, by Drug Class
10.1.1. Global Glioblastoma Multiforme Market Revenue Share, By Drug Class, 2023 Vs 2032 (in %)
10.2. Temozolomide
10.2.1. Global Glioblastoma Multiforme Market, By Temozolomide, By Region, 2019-2032 (US$ Mn)
10.2.2. Market Dynamics for Temozolomide
10.2.2.1. Drivers
10.2.2.2. Restraints
10.2.2.3. Opportunities
10.2.2.4. Trends
10.3. Carmustine
10.3.1. Global Glioblastoma Multiforme Market, By Carmustine, By Region, 2019-2032 (US$ Mn)
10.3.2. Market Dynamics for Carmustine
10.3.2.1. Drivers
10.3.2.2. Restraints
10.3.2.3. Opportunities
10.3.2.4. Trends
10.4. Lomustine
10.4.1. Global Glioblastoma Multiforme Market, By Lomustine, By Region, 2019-2032 (US$ Mn)
10.4.2. Market Dynamics for Lomustine
10.4.2.1. Drivers
10.4.2.2. Restraints
10.4.2.3. Opportunities
10.4.2.4. Trends
10.5. Others
10.5.1. Global Glioblastoma Multiforme Market, By Others, By Region, 2019-2032 (US$ Mn)
10.5.2. Market Dynamics for Others
10.5.2.1. Drivers
10.5.2.2. Restraints
10.5.2.3. Opportunities
10.5.2.4. Trends
11. Global Glioblastoma Multiforme Market, By Immunotherapy Agents
11.1. Global Glioblastoma Multiforme Market Overview, by Immunotherapy Agents
11.1.1. Global Glioblastoma Multiforme Market Revenue Share, By Immunotherapy Agents, 2023 Vs 2032 (in %)
11.2. Checkpoint Inhibitors
11.2.1. Global Glioblastoma Multiforme Market, By Checkpoint Inhibitors, By Region, 2019-2032 (US$ Mn)
11.2.2. Market Dynamics for Checkpoint Inhibitors
11.2.2.1. Drivers
11.2.2.2. Restraints
11.2.2.3. Opportunities
11.2.2.4. Trends
11.3. Vaccines
11.3.1. Global Glioblastoma Multiforme Market, By Vaccines, By Region, 2019-2032 (US$ Mn)
11.3.2. Market Dynamics for Vaccines
11.3.2.1. Drivers
11.3.2.2. Restraints
11.3.2.3. Opportunities
11.3.2.4. Trends
11.4. Others
11.4.1. Global Glioblastoma Multiforme Market, By Others, By Region, 2019-2032 (US$ Mn)
11.4.2. Market Dynamics for Others
11.4.2.1. Drivers
11.4.2.2. Restraints
11.4.2.3. Opportunities
11.4.2.4. Trends
12. Global Glioblastoma Multiforme Market, By Targeted Therapy Agents
12.1. Global Glioblastoma Multiforme Market Overview, by Targeted Therapy Agents
12.1.1. Global Glioblastoma Multiforme Market Revenue Share, By Targeted Therapy Agents, 2023 Vs 2032 (in %)
12.2. Bevacizumab
12.2.1. Global Glioblastoma Multiforme Market, By Bevacizumab, By Region, 2019-2032 (US$ Mn)
12.2.2. Market Dynamics for Bevacizumab
12.2.2.1. Drivers
12.2.2.2. Restraints
12.2.2.3. Opportunities
12.2.2.4. Trends
12.3. Erlotinib
12.3.1. Global Glioblastoma Multiforme Market, By Erlotinib, By Region, 2019-2032 (US$ Mn)
12.3.2. Market Dynamics for Erlotinib
12.3.2.1. Drivers
12.3.2.2. Restraints
12.3.2.3. Opportunities
12.3.2.4. Trends
12.4. Others
12.4.1. Global Glioblastoma Multiforme Market, By Others, By Region, 2019-2032 (US$ Mn)
12.4.2. Market Dynamics for Others
12.4.2.1. Drivers
12.4.2.2. Restraints
12.4.2.3. Opportunities
12.4.2.4. Trends
13. Global Glioblastoma Multiforme Market, By Clinical Trial Phase
13.1. Global Glioblastoma Multiforme Market Overview, by Clinical Trial Phase
13.1.1. Global Glioblastoma Multiforme Market Revenue Share, By Clinical Trial Phase, 2023 Vs 2032 (in %)
13.2. Phase I
13.2.1. Global Glioblastoma Multiforme Market, By Phase I, By Region, 2019-2032 (US$ Mn)
13.2.2. Market Dynamics for Phase I
13.2.2.1. Drivers
13.2.2.2. Restraints
13.2.2.3. Opportunities
13.2.2.4. Trends
13.3. Phase II
13.3.1. Global Glioblastoma Multiforme Market, By Phase II, By Region, 2019-2032 (US$ Mn)
13.3.2. Market Dynamics for Phase II
13.3.2.1. Drivers
13.3.2.2. Restraints
13.3.2.3. Opportunities
13.3.2.4. Trends
13.4. Phase III
13.4.1. Global Glioblastoma Multiforme Market, By Phase III, By Region, 2019-2032 (US$ Mn)
13.4.2. Market Dynamics for Phase III
13.4.2.1. Drivers
13.4.2.2. Restraints
13.4.2.3. Opportunities
13.4.2.4. Trends
13.5. Phase IV
13.5.1. Global Glioblastoma Multiforme Market, By Phase IV, By Region, 2019-2032 (US$ Mn)
13.5.2. Market Dynamics for Phase IV
13.5.2.1. Drivers
13.5.2.2. Restraints
13.5.2.3. Opportunities
13.5.2.4. Trends
14. Global Glioblastoma Multiforme Market, By Diagnostic Tools
14.1. Global Glioblastoma Multiforme Market Overview, by Diagnostic Tools
14.1.1. Global Glioblastoma Multiforme Market Revenue Share, By Diagnostic Tools, 2023 Vs 2032 (in %)
14.2. MRI
14.2.1. Global Glioblastoma Multiforme Market, By MRI, By Region, 2019-2032 (US$ Mn)
14.2.2. Market Dynamics for MRI
14.2.2.1. Drivers
14.2.2.2. Restraints
14.2.2.3. Opportunities
14.2.2.4. Trends
14.3. CT Scan
14.3.1. Global Glioblastoma Multiforme Market, By CT Scan, By Region, 2019-2032 (US$ Mn)
14.3.2. Market Dynamics for CT Scan
14.3.2.1. Drivers
14.3.2.2. Restraints
14.3.2.3. Opportunities
14.3.2.4. Trends
14.4. Biopsy
14.4.1. Global Glioblastoma Multiforme Market, By Biopsy, By Region, 2019-2032 (US$ Mn)
14.4.2. Market Dynamics for Biopsy
14.4.2.1. Drivers
14.4.2.2. Restraints
14.4.2.3. Opportunities
14.4.2.4. Trends
15. Global Glioblastoma Multiforme Market, By Region
15.1. Global Glioblastoma Multiforme Market Overview, by Region
15.1.1. Global Glioblastoma Multiforme Market, By Region, 2023 vs 2032 (in%)
15.2. Surgery
15.2.1. Global Glioblastoma Multiforme Market, By Surgery, 2019-2032 (US$ Mn)
15.3. End-User
15.3.1. Global Glioblastoma Multiforme Market, By End-User, 2019-2032 (US$ Mn)
15.4. Drug Class
15.4.1. Global Glioblastoma Multiforme Market, By Drug Class, 2019-2032 (US$ Mn)
15.5. Immunotherapy Agents
15.5.1. Global Glioblastoma Multiforme Market, By Immunotherapy Agents, 2019-2032 (US$ Mn)
15.6. Targeted Therapy Agents
15.6.1. Global Glioblastoma Multiforme Market, By Targeted Therapy Agents, 2019-2032 (US$ Mn)
15.7. Clinical Trial Phase
15.7.1. Global Glioblastoma Multiforme Market, By Clinical Trial Phase, 2019-2032 (US$ Mn)
15.8. Diagnostic Tools
15.8.1. Global Glioblastoma Multiforme Market, By Diagnostic Tools, 2019-2032 (US$ Mn)
16. North America Glioblastoma Multiforme Market Analysis
16.1. Overview
16.1.1. Market Dynamics for North America
16.1.1.1. Drivers
16.1.1.2. Restraints
16.1.1.3. Opportunities
16.1.1.4. Trends
16.2. North America Glioblastoma Multiforme Market, by Surgery, 2019-2032(US$ Mn)
16.2.1. Overview
16.2.2. SRC Analysis
16.3. North America Glioblastoma Multiforme Market, by End-User, 2019-2032(US$ Mn)
16.3.1. Overview
16.3.2. SRC Analysis
16.4. North America Glioblastoma Multiforme Market, by Drug Class, 2019-2032(US$ Mn)
16.4.1. Overview
16.4.2. SRC Analysis
16.5. North America Glioblastoma Multiforme Market, by Immunotherapy Agents, 2019-2032(US$ Mn)
16.5.1. Overview
16.5.2. SRC Analysis
16.6. North America Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2032(US$ Mn)
16.6.1. Overview
16.6.2. SRC Analysis
16.7. North America Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2032(US$ Mn)
16.7.1. Overview
16.7.2. SRC Analysis
16.8. North America Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2032(US$ Mn)
16.8.1. Overview
16.8.2. SRC Analysis
16.9. North America Glioblastoma Multiforme Market, by Country, 2019-2032 (US$ Mn)
16.9.1. North America Glioblastoma Multiforme Market, by Country, 2023 Vs 2032 (in%)
16.9.2. U.S.
16.9.3. Canada
16.9.4. Mexico
17. Europe Glioblastoma Multiforme Market Analysis
17.1. Overview
17.1.1. Market Dynamics for North America
17.1.1.1. Drivers
17.1.1.2. Restraints
17.1.1.3. Opportunities
17.1.1.4. Trends
17.2. Europe Glioblastoma Multiforme Market, by Surgery, 2019-2032(US$ Mn)
17.2.1. Overview
17.2.2. SRC Analysis
17.3. Europe Glioblastoma Multiforme Market, by End-User, 2019-2032(US$ Mn)
17.3.1. Overview
17.3.2. SRC Analysis
17.4. Europe Glioblastoma Multiforme Market, by Drug Class, 2019-2032(US$ Mn)
17.4.1. Overview
17.4.2. SRC Analysis
17.5. Europe Glioblastoma Multiforme Market, by Immunotherapy Agents, 2019-2032(US$ Mn)
17.5.1. Overview
17.5.2. SRC Analysis
17.6. Europe Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2032(US$ Mn)
17.6.1. Overview
17.6.2. SRC Analysis
17.7. Europe Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2032(US$ Mn)
17.7.1. Overview
17.7.2. SRC Analysis
17.8. Europe Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2032(US$ Mn)
17.8.1. Overview
17.8.2. SRC Analysis
17.9. Europe Glioblastoma Multiforme Market, by Country, 2019-2032 (US$ Mn)
17.9.1. Europe Glioblastoma Multiforme Market, by Country, 2023 Vs 2032 (in%)
17.9.2. UK
17.9.3. France
17.9.4. Germany
17.9.5. Italy
17.9.6. Spain
17.9.7. Benelux
17.9.8. Russia
17.9.9. Rest of Europe
18. Asia Pacific Glioblastoma Multiforme Market Analysis
18.1. Overview
18.1.1. Market Dynamics for North America
18.1.1.1. Drivers
18.1.1.2. Restraints
18.1.1.3. Opportunities
18.1.1.4. Trends
18.2. Asia Pacific Glioblastoma Multiforme Market, by Surgery, 2019-2032(US$ Mn)
18.2.1. Overview
18.2.2. SRC Analysis
18.3. Asia Pacific Glioblastoma Multiforme Market, by End-User, 2019-2032(US$ Mn)
18.3.1. Overview
18.3.2. SRC Analysis
18.4. Asia Pacific Glioblastoma Multiforme Market, by Drug Class, 2019-2032(US$ Mn)
18.4.1. Overview
18.4.2. SRC Analysis
18.5. Asia Pacific Glioblastoma Multiforme Market, by Immunotherapy Agents, 2019-2032(US$ Mn)
18.5.1. Overview
18.5.2. SRC Analysis
18.6. Asia Pacific Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2032(US$ Mn)
18.6.1. Overview
18.6.2. SRC Analysis
18.7. Asia Pacific Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2032(US$ Mn)
18.7.1. Overview
18.7.2. SRC Analysis
18.8. Asia Pacific Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2032(US$ Mn)
18.8.1. Overview
18.8.2. SRC Analysis
18.9. Asia Pacific Glioblastoma Multiforme Market, by Country, 2019-2032 (US$ Mn)
18.9.1. Asia Pacific Glioblastoma Multiforme Market, by Country, 2023 Vs 2032 (in%)
18.9.2. China
18.9.3. Japan
18.9.4. India
18.9.5. South Korea
18.9.6. South East Asia
18.9.7. Rest of Asia Pacific
19. Latin America Glioblastoma Multiforme Market Analysis
19.1. Overview
19.1.1. Market Dynamics for North America
19.1.1.1. Drivers
19.1.1.2. Restraints
19.1.1.3. Opportunities
19.1.1.4. Trends
19.2. Latin America Glioblastoma Multiforme Market, by Surgery, 2019-2032(US$ Mn)
19.2.1. Overview
19.2.2. SRC Analysis
19.3. Latin America Glioblastoma Multiforme Market, by End-User, 2019-2032(US$ Mn)
19.3.1. Overview
19.3.2. SRC Analysis
19.4. Latin America Glioblastoma Multiforme Market, by Drug Class, 2019-2032(US$ Mn)
19.4.1. Overview
19.4.2. SRC Analysis
19.5. Latin America Glioblastoma Multiforme Market, by Immunotherapy Agents, 2019-2032(US$ Mn)
19.5.1. Overview
19.5.2. SRC Analysis
19.6. Latin America Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2032(US$ Mn)
19.6.1. Overview
19.6.2. SRC Analysis
19.7. Latin America Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2032(US$ Mn)
19.7.1. Overview
19.7.2. SRC Analysis
19.8. Latin America Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2032(US$ Mn)
19.8.1. Overview
19.8.2. SRC Analysis
19.9. Latin America Glioblastoma Multiforme Market, by Country, 2019-2032 (US$ Mn)
19.9.1. Latin America Glioblastoma Multiforme Market, by Country, 2023 Vs 2032 (in%)
19.9.2. Brazil
19.9.3. Argentina
19.9.4. Rest of Latin America
20. Middle East Glioblastoma Multiforme Market Analysis
20.1. Overview
20.1.1. Market Dynamics for North America
20.1.1.1. Drivers
20.1.1.2. Restraints
20.1.1.3. Opportunities
20.1.1.4. Trends
20.2. Middle East Glioblastoma Multiforme Market, by Surgery, 2019-2032(US$ Mn)
20.2.1. Overview
20.2.2. SRC Analysis
20.3. Middle East Glioblastoma Multiforme Market, by End-User, 2019-2032(US$ Mn)
20.3.1. Overview
20.3.2. SRC Analysis
20.4. Middle East Glioblastoma Multiforme Market, by Drug Class, 2019-2032(US$ Mn)
20.4.1. Overview
20.4.2. SRC Analysis
20.5. Middle East Glioblastoma Multiforme Market, by Immunotherapy Agents, 2019-2032(US$ Mn)
20.5.1. Overview
20.5.2. SRC Analysis
20.6. Middle East Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2032(US$ Mn)
20.6.1. Overview
20.6.2. SRC Analysis
20.7. Middle East Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2032(US$ Mn)
20.7.1. Overview
20.7.2. SRC Analysis
20.8. Middle East Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2032(US$ Mn)
20.8.1. Overview
20.8.2. SRC Analysis
20.9. Middle East Glioblastoma Multiforme Market, by Country, 2019-2032 (US$ Mn)
20.9.1. Middle East Glioblastoma Multiforme Market, by Country, 2023 Vs 2032 (in%)
20.9.2. UAE
20.9.3. Saudi Arabia
20.9.4. Rest of Middle East
21. Africa Glioblastoma Multiforme Market Analysis
21.1. Overview
21.1.1. Market Dynamics for North America
21.1.1.1. Drivers
21.1.1.2. Restraints
21.1.1.3. Opportunities
21.1.1.4. Trends
21.2. Africa Glioblastoma Multiforme Market, by Surgery, 2019-2032(US$ Mn)
21.2.1. Overview
21.2.2. SRC Analysis
21.3. Africa Glioblastoma Multiforme Market, by End-User, 2019-2032(US$ Mn)
21.3.1. Overview
21.3.2. SRC Analysis
21.4. Africa Glioblastoma Multiforme Market, by Drug Class, 2019-2032(US$ Mn)
21.4.1. Overview
21.4.2. SRC Analysis
21.5. Africa Glioblastoma Multiforme Market, by Immunotherapy Agents, 2019-2032(US$ Mn)
21.5.1. Overview
21.5.2. SRC Analysis
21.6. Africa Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2032(US$ Mn)
21.6.1. Overview
21.6.2. SRC Analysis
21.7. Africa Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2032(US$ Mn)
21.7.1. Overview
21.7.2. SRC Analysis
21.8. Africa Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2032(US$ Mn)
21.8.1. Overview
21.8.2. SRC Analysis
21.9. Africa Glioblastoma Multiforme Market, by Country, 2019-2032 (US$ Mn)
21.9.1. Middle East Glioblastoma Multiforme Market, by Country, 2023 Vs 2032 (in%)
21.9.2. South Africa
21.9.3. Egypt
21.9.4. Rest of Africa
22. Company Profiles
22.1. Merck & Co. Inc
22.1.1. Company Overview
22.1.2. Products/Services Portfolio
22.1.3. Geographical Presence
22.1.4. SWOT Analysis
22.1.5. Financial Summary
22.1.5.1. Market Revenue and Net Profit (2019-2023)
22.1.5.2. Business Segment Revenue Analysis
22.1.5.3. Geographical Revenue Analysis
22.2. Amgen Inc
22.3. F. Hoffmann-La Roche Ltd
22.4. Pfizer Inc
22.5. Teva Pharmaceutical Industries Ltd
22.6. Sun Pharmaceutical Industries Ltd
22.7. Arbor Pharmaceuticals LLC
22.8. Amneal Pharmaceuticals
22.9. Karyopharm Therapeutics Inc
22.10. Others
23. Research Methodology
23.1. Research Methodology
23.2. Phase I – Secondary Research
23.3. Phase II – Data Modelling
23.3.1. Company Share Analysis Model
23.3.2. Revenue Based Modelling
23.4. Phase III – Primary Research
23.5. Research Limitations
23.5.1. Assumptions

List of Figures
FIG. 1 Global Glioblastoma Multiforme Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Global Glioblastoma Multiforme Market Segmentation
FIG. 4 Global Glioblastoma Multiforme Market, by Surgery, 2023 (US$ Mn)
FIG. 5 Global Glioblastoma Multiforme Market, by End-User, 2023 (US$ Mn)
FIG. 6 Global Glioblastoma Multiforme Market, by Drug Class, 2023 (US$ Mn)
FIG. 7 Global Glioblastoma Multiforme Market, by Immunotherapy Agents, 2023 (US$ Mn)
FIG. 8 Global Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2023 (US$ Mn)
FIG. 9 Global Glioblastoma Multiforme Market, by Clinical Trial Phase, 2023 (US$ Mn)
FIG. 10 Global Glioblastoma Multiforme Market, by Diagnostic Tools, 2023 (US$ Mn)
FIG. 11 Global Glioblastoma Multiforme Market, by Geography, 2023 (US$ Mn)
FIG. 12 Attractive Investment Proposition, by Surgery, 2023
FIG. 13 Attractive Investment Proposition, by End-User, 2023
FIG. 14 Attractive Investment Proposition, by Drug Class, 2023
FIG. 15 Attractive Investment Proposition, by Immunotherapy Agents, 2023
FIG. 16 Attractive Investment Proposition, by Targeted Therapy Agents, 2023
FIG. 17 Attractive Investment Proposition, by Clinical Trial Phase, 2023
FIG. 18 Attractive Investment Proposition, by Diagnostic Tools, 2023
FIG. 19 Attractive Investment Proposition, by Geography, 2023
FIG. 20 Global Market Share Analysis of Key Glioblastoma Multiforme Market Manufacturers, 2023
FIG. 21 Global Market Positioning of Key Glioblastoma Multiforme Market Manufacturers, 2023
FIG. 22 Global Glioblastoma Multiforme Market Value Contribution, By Surgery, 2023 & 2032 (Value %)
FIG. 23 Global Glioblastoma Multiforme Market, by Radiation Therapy, Value, 2019-2032 (US$ Mn)
FIG. 24 Global Glioblastoma Multiforme Market, by Chemotherapy, Value, 2019-2032 (US$ Mn)
FIG. 25 Global Glioblastoma Multiforme Market, by Immunotherapy, Value, 2019-2032 (US$ Mn)
FIG. 26 Global Glioblastoma Multiforme Market, by Targeted Therapy, Value, 2019-2032 (US$ Mn)
FIG. 27 Global Glioblastoma Multiforme Market, by Tumor Treating Fields (TTF) Therapy, Value, 2019-2032 (US$ Mn)
FIG. 28 Global Glioblastoma Multiforme Market, by Supportive Care, Value, 2019-2032 (US$ Mn)
FIG. 29 Global Glioblastoma Multiforme Market Value Contribution, By End-User, 2023 & 2032 (Value %)
FIG. 30 Global Glioblastoma Multiforme Market, by Hospitals, Value, 2019-2032 (US$ Mn)
FIG. 31 Global Glioblastoma Multiforme Market, by Cancer Research Institutes, Value, 2019-2032 (US$ Mn)
FIG. 32 Global Glioblastoma Multiforme Market, by Ambulatory Surgical Centers, Value, 2019-2032 (US$ Mn)
FIG. 33 Global Glioblastoma Multiforme Market, by Others, Value, 2019-2032 (US$ Mn)
FIG. 34 Global Glioblastoma Multiforme Market Value Contribution, By Drug Class, 2023 & 2032 (Value %)
FIG. 35 Global Glioblastoma Multiforme Market, by Temozolomide, Value, 2019-2032 (US$ Mn)
FIG. 36 Global Glioblastoma Multiforme Market, by Carmustine, Value, 2019-2032 (US$ Mn)
FIG. 37 Global Glioblastoma Multiforme Market, by Lomustine, Value, 2019-2032 (US$ Mn)
FIG. 38 Global Glioblastoma Multiforme Market, by Others, Value, 2019-2032 (US$ Mn)
FIG. 39 Global Glioblastoma Multiforme Market Value Contribution, By Immunotherapy Agents, 2023 & 2032 (Value %)
FIG. 40 Global Glioblastoma Multiforme Market, by Checkpoint Inhibitors, Value, 2019-2032 (US$ Mn)
FIG. 41 Global Glioblastoma Multiforme Market, by Vaccines, Value, 2019-2032 (US$ Mn)
FIG. 42 Global Glioblastoma Multiforme Market, by Others, Value, 2019-2032 (US$ Mn)
FIG. 43 Global Glioblastoma Multiforme Market Value Contribution, By Targeted Therapy Agents, 2023 & 2032 (Value %)
FIG. 44 Global Glioblastoma Multiforme Market, by Bevacizumab, Value, 2019-2032 (US$ Mn)
FIG. 45 Global Glioblastoma Multiforme Market, by Erlotinib, Value, 2019-2032 (US$ Mn)
FIG. 46 Global Glioblastoma Multiforme Market, by Others, Value, 2019-2032 (US$ Mn)
FIG. 47 Global Glioblastoma Multiforme Market Value Contribution, By Clinical Trial Phase, 2023 & 2032 (Value %)
FIG. 48 Global Glioblastoma Multiforme Market, by Phase I, Value, 2019-2032 (US$ Mn)
FIG. 49 Global Glioblastoma Multiforme Market, by Phase II, Value, 2019-2032 (US$ Mn)
FIG. 50 Global Glioblastoma Multiforme Market, by Phase III, Value, 2019-2032 (US$ Mn)
FIG. 51 Global Glioblastoma Multiforme Market, by Phase IV, Value, 2019-2032 (US$ Mn)
FIG. 52 Global Glioblastoma Multiforme Market Value Contribution, By Diagnostic Tools, 2023 & 2032 (Value %)
FIG. 53 Global Glioblastoma Multiforme Market, by MRI, Value, 2019-2032 (US$ Mn)
FIG. 54 Global Glioblastoma Multiforme Market, by CT Scan, Value, 2019-2032 (US$ Mn)
FIG. 55 Global Glioblastoma Multiforme Market, by Biopsy, Value, 2019-2032 (US$ Mn)
FIG. 56 North America Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 57 U.S. Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 58 Canada Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 59 Mexico Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 60 Europe Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 61 Germany Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 62 France Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 63 U.K. Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 64 Italy Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 65 Spain Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 66 Benelux Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 67 Russia Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 68 Rest of Europe Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 69 Asia Pacific Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 70 China Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 71 Japan Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 72 India Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 73 South Korea Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 74 South-East Asia Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 75 Rest of Asia Pacific Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 76 Latin America Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 77 Brazil Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 78 Argentina Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 79 Rest of Latin America Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 80 Middle East Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 81 UAE Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 82 Saudi Arabia Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 83 Rest of Middle East Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 84 Africa Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 85 South Africa Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 86 Egypt Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 87 Rest of Africa Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)

List of Tables
TABLE 1 Market Snapshot: Global Glioblastoma Multiforme Market
TABLE 2 Global Glioblastoma Multiforme Market: Market Drivers Impact Analysis
TABLE 3 Global Glioblastoma Multiforme Market: Market Restraints Impact Analysis
TABLE 4 Global Glioblastoma Multiforme Market, by Competitive Benchmarking, 2023
TABLE 5 Global Glioblastoma Multiforme Market, by Geographical Presence Analysis, 2023
TABLE 6 Global Glioblastoma Multiforme Market, by Key Strategies Analysis, 2023
TABLE 7 Global Glioblastoma Multiforme Market, by Radiation Therapy, By Region, 2019-2023 (US$ Mn)
TABLE 8 Global Glioblastoma Multiforme Market, by Radiation Therapy, By Region, 2024-2032 (US$ Mn)
TABLE 9 Global Glioblastoma Multiforme Market, by Chemotherapy, By Region, 2019-2023 (US$ Mn)
TABLE 10 Global Glioblastoma Multiforme Market, by Chemotherapy, By Region, 2024-2032 (US$ Mn)
TABLE 11 Global Glioblastoma Multiforme Market, by Immunotherapy, By Region, 2019-2023 (US$ Mn)
TABLE 12 Global Glioblastoma Multiforme Market, by Immunotherapy, By Region, 2024-2032 (US$ Mn)
TABLE 13 Global Glioblastoma Multiforme Market, by Targeted Therapy, By Region, 2019-2023 (US$ Mn)
TABLE 14 Global Glioblastoma Multiforme Market, by Targeted Therapy, By Region, 2024-2032 (US$ Mn)
TABLE 15 Global Glioblastoma Multiforme Market, by Tumor Treating Fields (TTF) Therapy, By Region, 2019-2023 (US$ Mn)
TABLE 16 Global Glioblastoma Multiforme Market, by Tumor Treating Fields (TTF) Therapy, By Region, 2024-2032 (US$ Mn)
TABLE 17 Global Glioblastoma Multiforme Market, by Supportive Care, By Region, 2019-2023 (US$ Mn)
TABLE 18 Global Glioblastoma Multiforme Market, by Supportive Care, By Region, 2024-2032 (US$ Mn)
TABLE 19 Global Glioblastoma Multiforme Market, by Hospitals, By Region, 2019-2023 (US$ Mn)
TABLE 20 Global Glioblastoma Multiforme Market, by Hospitals, By Region, 2024-2032 (US$ Mn)
TABLE 21 Global Glioblastoma Multiforme Market, by Cancer Research Institutes, By Region, 2019-2023 (US$ Mn)
TABLE 22 Global Glioblastoma Multiforme Market, by Cancer Research Institutes, By Region, 2024-2032 (US$ Mn)
TABLE 23 Global Glioblastoma Multiforme Market, by Ambulatory Surgical Centers, By Region, 2019-2023 (US$ Mn)
TABLE 24 Global Glioblastoma Multiforme Market, by Ambulatory Surgical Centers, By Region, 2024-2032 (US$ Mn)
TABLE 25 Global Glioblastoma Multiforme Market, by Others, By Region, 2019-2023 (US$ Mn)
TABLE 26 Global Glioblastoma Multiforme Market, by Others, By Region, 2024-2032 (US$ Mn)
TABLE 27 Global Glioblastoma Multiforme Market, by Temozolomide, By Region, 2019-2023 (US$ Mn)
TABLE 28 Global Glioblastoma Multiforme Market, by Temozolomide, By Region, 2024-2032 (US$ Mn)
TABLE 29 Global Glioblastoma Multiforme Market, by Carmustine, By Region, 2019-2023 (US$ Mn)
TABLE 30 Global Glioblastoma Multiforme Market, by Carmustine, By Region, 2024-2032 (US$ Mn)
TABLE 31 Global Glioblastoma Multiforme Market, by Lomustine, By Region, 2019-2023 (US$ Mn)
TABLE 32 Global Glioblastoma Multiforme Market, by Lomustine, By Region, 2024-2032 (US$ Mn)
TABLE 33 Global Glioblastoma Multiforme Market, by Others, By Region, 2019-2023 (US$ Mn)
TABLE 34 Global Glioblastoma Multiforme Market, by Others, By Region, 2024-2032 (US$ Mn)
TABLE 35 Global Glioblastoma Multiforme Market, by Checkpoint Inhibitors, By Region, 2019-2023 (US$ Mn)
TABLE 36 Global Glioblastoma Multiforme Market, by Checkpoint Inhibitors, By Region, 2024-2032 (US$ Mn)
TABLE 37 Global Glioblastoma Multiforme Market, by Vaccines, By Region, 2019-2023 (US$ Mn)
TABLE 38 Global Glioblastoma Multiforme Market, by Vaccines, By Region, 2024-2032 (US$ Mn)
TABLE 39 Global Glioblastoma Multiforme Market, by Others, By Region, 2019-2023 (US$ Mn)
TABLE 40 Global Glioblastoma Multiforme Market, by Others, By Region, 2024-2032 (US$ Mn)
TABLE 41 Global Glioblastoma Multiforme Market, by Bevacizumab, By Region, 2019-2023 (US$ Mn)
TABLE 42 Global Glioblastoma Multiforme Market, by Bevacizumab, By Region, 2024-2032 (US$ Mn)
TABLE 43 Global Glioblastoma Multiforme Market, by Erlotinib, By Region, 2019-2023 (US$ Mn)
TABLE 44 Global Glioblastoma Multiforme Market, by Erlotinib, By Region, 2024-2032 (US$ Mn)
TABLE 45 Global Glioblastoma Multiforme Market, by Others, By Region, 2019-2023 (US$ Mn)
TABLE 46 Global Glioblastoma Multiforme Market, by Others, By Region, 2024-2032 (US$ Mn)
TABLE 47 Global Glioblastoma Multiforme Market, by Phase I, By Region, 2019-2023 (US$ Mn)
TABLE 48 Global Glioblastoma Multiforme Market, by Phase I, By Region, 2024-2032 (US$ Mn)
TABLE 49 Global Glioblastoma Multiforme Market, by Phase II, By Region, 2019-2023 (US$ Mn)
TABLE 50 Global Glioblastoma Multiforme Market, by Phase II, By Region, 2024-2032 (US$ Mn)
TABLE 51 Global Glioblastoma Multiforme Market, by Phase III, By Region, 2019-2023 (US$ Mn)
TABLE 52 Global Glioblastoma Multiforme Market, by Phase III, By Region, 2024-2032 (US$ Mn)
TABLE 53 Global Glioblastoma Multiforme Market, by Phase IV, By Region, 2019-2023 (US$ Mn)
TABLE 54 Global Glioblastoma Multiforme Market, by Phase IV, By Region, 2024-2032 (US$ Mn)
TABLE 55 Global Glioblastoma Multiforme Market, by MRI, By Region, 2019-2023 (US$ Mn)
TABLE 56 Global Glioblastoma Multiforme Market, by MRI, By Region, 2024-2032 (US$ Mn)
TABLE 57 Global Glioblastoma Multiforme Market, by CT Scan, By Region, 2019-2023 (US$ Mn)
TABLE 58 Global Glioblastoma Multiforme Market, by CT Scan, By Region, 2024-2032 (US$ Mn)
TABLE 59 Global Glioblastoma Multiforme Market, by Biopsy, By Region, 2019-2023 (US$ Mn)
TABLE 60 Global Glioblastoma Multiforme Market, by Biopsy, By Region, 2024-2032 (US$ Mn)
TABLE 61 Global Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 62 Global Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 63 Global Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 64 Global Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 65 Global Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 66 Global Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 67 Global Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 68 Global Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 69 Global Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 70 Global Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 71 Global Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 72 Global Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 73 Global Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 74 Global Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 75 Global Glioblastoma Multiforme Market, by Region, 2019-2023 (US$ Mn)
TABLE 76 Global Glioblastoma Multiforme Market, by Region, 2024-2032 (US$ Mn)
TABLE 77 North America Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 78 North America Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 79 North America Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 80 North America Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 81 North America Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 82 North America Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 83 North America Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 84 North America Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 85 North America Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 86 North America Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 87 North America Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 88 North America Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 89 North America Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 90 North America Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 91 North America Glioblastoma Multiforme Market, by Country, 2019-2023 (US$ Mn)
TABLE 92 North America Glioblastoma Multiforme Market, by Country, 2024-2032 (US$ Mn)
TABLE 93 United States Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 94 United States Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 95 United States Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 96 United States Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 97 United States Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 98 United States Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 99 United States Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 100 United States Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 101 United States Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 102 United States Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 103 United States Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 104 United States Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 105 United States Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 106 United States Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 107 Canada Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 108 Canada Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 109 Canada Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 110 Canada Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 111 Canada Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 112 Canada Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 113 Canada Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 114 Canada Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 115 Canada Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 116 Canada Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 117 Canada Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 118 Canada Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 119 Canada Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 120 Canada Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 121 Mexico Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 122 Mexico Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 123 Mexico Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 124 Mexico Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 125 Mexico Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 126 Mexico Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 127 Mexico Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 128 Mexico Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 129 Mexico Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 130 Mexico Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 131 Mexico Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 132 Mexico Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 133 Mexico Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 134 Mexico Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 135 Europe Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 136 Europe Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 137 Europe Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 138 Europe Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 139 Europe Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 140 Europe Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 141 Europe Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 142 Europe Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 143 Europe Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 144 Europe Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 145 Europe Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 146 Europe Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 147 Europe Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 148 Europe Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 149 Europe Glioblastoma Multiforme Market, by Country, 2019-2023 (US$ Mn)
TABLE 150 Europe Glioblastoma Multiforme Market, by Country, 2024-2032 (US$ Mn)
TABLE 151 Germany Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 152 Germany Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 153 Germany Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 154 Germany Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 155 Germany Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 156 Germany Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 157 Germany Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 158 Germany Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 159 Germany Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 160 Germany Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 161 Germany Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 162 Germany Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 163 Germany Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 164 Germany Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 165 France Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 166 France Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 167 France Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 168 France Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 169 France Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 170 France Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 171 France Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 172 France Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 173 France Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 174 France Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 175 France Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 176 France Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 177 France Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 178 France Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 179 United Kingdom Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 180 United Kingdom Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 181 United Kingdom Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 182 United Kingdom Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 183 United Kingdom Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 184 United Kingdom Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 185 United Kingdom Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 186 United Kingdom Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 187 United Kingdom Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 188 United Kingdom Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 189 United Kingdom Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 190 United Kingdom Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 191 United Kingdom Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 192 United Kingdom Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 193 Italy Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 194 Italy Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 195 Italy Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 196 Italy Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 197 Italy Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 198 Italy Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 199 Italy Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 200 Italy Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 201 Italy Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 202 Italy Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 203 Italy Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 204 Italy Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 205 Italy Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 206 Italy Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 207 Spain Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 208 Spain Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 209 Spain Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 210 Spain Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 211 Spain Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 212 Spain Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 213 Spain Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 214 Spain Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 215 Spain Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 216 Spain Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 217 Spain Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 218 Spain Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 219 Spain Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 220 Spain Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 221 Benelux Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 222 Benelux Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 223 Benelux Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 224 Benelux Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 225 Benelux Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 226 Benelux Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 227 Benelux Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 228 Benelux Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 229 Benelux Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 230 Benelux Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 231 Benelux Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 232 Benelux Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 233 Benelux Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 234 Benelux Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 235 Russia Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 236 Russia Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 237 Russia Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 238 Russia Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 239 Russia Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 240 Russia Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 241 Russia Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 242 Russia Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 243 Russia Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 244 Russia Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 245 Russia Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 246 Russia Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 247 Russia Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 248 Russia Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 249 Rest of Europe Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 250 Rest of Europe Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 251 Rest of Europe Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 252 Rest of Europe Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 253 Rest of Europe Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 254 Rest of Europe Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 255 Rest of Europe Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 256 Rest of Europe Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 257 Rest of Europe Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 258 Rest of Europe Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 259 Rest of Europe Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 260 Rest of Europe Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 261 Rest of Europe Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 262 Rest of Europe Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 263 Asia Pacific Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 264 Asia Pacific Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 265 Asia Pacific Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 266 Asia Pacific Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 267 Asia Pacific Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 268 Asia Pacific Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 269 Asia Pacific Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 270 Asia Pacific Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 271 Asia Pacific Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 272 Asia Pacific Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 273 Asia Pacific Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 274 Asia Pacific Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 275 Asia Pacific Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 276 Asia Pacific Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 277 China Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 278 China Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 279 China Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 280 China Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 281 China Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 282 China Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 283 China Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 284 China Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 285 China Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 286 China Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 287 China Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 288 China Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 289 China Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 290 China Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 291 Japan Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 292 Japan Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 293 Japan Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 294 Japan Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 295 Japan Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 296 Japan Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 297 Japan Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 298 Japan Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 299 Japan Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 300 Japan Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 301 Japan Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 302 Japan Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 303 Japan Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 304 Japan Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 305 India Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 306 India Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 307 India Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 308 India Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 309 India Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 310 India Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 311 India Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 312 India Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 313 India Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 314 India Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 315 India Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 316 India Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 317 India Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 318 India Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 319 South Korea Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 320 South Korea Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 321 South Korea Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 322 South Korea Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 323 South Korea Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 324 South Korea Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 325 South Korea Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 326 South Korea Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 327 South Korea Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 328 South Korea Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 329 South Korea Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 330 South Korea Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 331 South Korea Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 332 South Korea Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 333 South-East Asia Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 334 South-East Asia Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 335 South-East Asia Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 336 South-East Asia Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 337 South-East Asia Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 338 South-East Asia Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 339 South-East Asia Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 340 South-East Asia Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 341 South-East Asia Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 342 South-East Asia Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 343 South-East Asia Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 344 South-East Asia Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 345 South-East Asia Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 346 South-East Asia Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 347 Rest of Asia Pacific Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 348 Rest of Asia Pacific Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 349 Rest of Asia Pacific Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 350 Rest of Asia Pacific Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 351 Rest of Asia Pacific Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 352 Rest of Asia Pacific Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 353 Rest of Asia Pacific Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 354 Rest of Asia Pacific Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 355 Rest of Asia Pacific Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 356 Rest of Asia Pacific Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 357 Rest of Asia Pacific Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 358 Rest of Asia Pacific Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 359 Rest of Asia Pacific Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 360 Rest of Asia Pacific Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 361 Latin America Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 362 Latin America Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 363 Latin America Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 364 Latin America Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 365 Latin America Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 366 Latin America Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 367 Latin America Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 368 Latin America Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 369 Latin America Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 370 Latin America Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 371 Latin America Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 372 Latin America Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 373 Latin America Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 374 Latin America Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 375 Brazil Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 376 Brazil Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 377 Brazil Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 378 Brazil Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 379 Brazil Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 380 Brazil Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 381 Brazil Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 382 Brazil Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 383 Brazil Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 384 Brazil Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 385 Brazil Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 386 Brazil Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 387 Brazil Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 388 Brazil Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 389 Argentina Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 390 Argentina Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 391 Argentina Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 392 Argentina Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 393 Argentina Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 394 Argentina Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 395 Argentina Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 396 Argentina Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 397 Argentina Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 398 Argentina Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 399 Argentina Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 400 Argentina Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 401 Argentina Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 402 Argentina Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 403 Rest of Latin America Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 404 Rest of Latin America Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 405 Rest of Latin America Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 406 Rest of Latin America Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 407 Rest of Latin America Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 408 Rest of Latin America Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 409 Rest of Latin America Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 410 Rest of Latin America Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 411 Rest of Latin America Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 412 Rest of Latin America Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 413 Rest of Latin America Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 414 Rest of Latin America Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 415 Rest of Latin America Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 416 Rest of Latin America Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 417 Middle East Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 418 Middle East Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 419 Middle East Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 420 Middle East Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 421 Middle East Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 422 Middle East Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 423 Middle East Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 424 Middle East Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 425 Middle East Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 426 Middle East Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 427 Middle East Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 428 Middle East Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 429 Middle East Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 430 Middle East Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 431 UAE Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 432 UAE Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 433 UAE Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 434 UAE Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 435 UAE Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 436 UAE Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 437 UAE Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 438 UAE Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 439 UAE Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 440 UAE Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 441 UAE Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 442 UAE Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 443 UAE Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 444 UAE Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 445 Saudi Arabia Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 446 Saudi Arabia Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 447 Saudi Arabia Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 448 Saudi Arabia Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 449 Saudi Arabia Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 450 Saudi Arabia Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 451 Saudi Arabia Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 452 Saudi Arabia Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 453 Saudi Arabia Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 454 Saudi Arabia Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 455 Saudi Arabia Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 456 Saudi Arabia Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 457 Saudi Arabia Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 458 Saudi Arabia Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 459 Rest of Middle East Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 460 Rest of Middle East Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 461 Rest of Middle East Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 462 Rest of Middle East Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 463 Rest of Middle East Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 464 Rest of Middle East Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 465 Rest of Middle East Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 466 Rest of Middle East Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 467 Rest of Middle East Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 468 Rest of Middle East Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 469 Rest of Middle East Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 470 Rest of Middle East Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 471 Rest of Middle East Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 472 Rest of Middle East Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 473 Africa Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 474 Africa Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 475 Africa Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 476 Africa Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 477 Africa Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 478 Africa Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 479 Africa Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 480 Africa Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 481 Africa Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 482 Africa Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 483 Africa Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 484 Africa Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 485 Africa Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 486 Africa Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 487 South Africa Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 488 South Africa Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 489 South Africa Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 490 South Africa Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 491 South Africa Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 492 South Africa Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 493 South Africa Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 494 South Africa Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 495 South Africa Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 496 South Africa Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 497 South Africa Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 498 South Africa Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 499 South Africa Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 500 South Africa Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 501 Egypt Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 502 Egypt Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 503 Egypt Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 504 Egypt Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 505 Egypt Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 506 Egypt Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 507 Egypt Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 508 Egypt Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 509 Egypt Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 510 Egypt Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 511 Egypt Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 512 Egypt Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 513 Egypt Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 514 Egypt Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 515 Rest of Africa Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 516 Rest of Africa Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 517 Rest of Africa Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 518 Rest of Africa Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 519 Rest of Africa Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 520 Rest of Africa Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 521 Rest of Africa Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 522 Rest of Africa Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 523 Rest of Africa Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 524 Rest of Africa Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 525 Rest of Africa Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 526 Rest of Africa Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 527 Rest of Africa Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 528 Rest of Africa Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)

Frequently Asked Questions

What is the current size of the global glioblastoma multiforme market?

The global glioblastoma multiforme market was valued at USD 2512.5 Million in 2023.

What is the expected growth rate of the glioblastoma multiforme market between 2024 and 2032?

The glioblastoma multiforme market is expected to grow at a CAGR of 9.2% between 2024 and 2032, reaching USD 5547.7 Million in 2032.

Which category is leading the market revenue in terms of surgery?

Radiation therapy is the leading segment by surgery, holding over 20% share in value in 2023.

Which region is fueling the growth of the glioblastoma multiforme industry?

North America is fueling the growth of the glioblastoma multiforme industry, with over one-third market share in 2023.

Who are the major players in the global glioblastoma multiforme market?

The top players include Merck & Co. Inc., Amgen Inc., F. Hoffmann-La Roche Ltd, Pfizer Inc., Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Arbor Pharmaceuticals LLC, Amneal Pharmaceuticals, Karyopharm Therapeutics Inc., Others.

Animal Drug Compounding Market

Published:
Report ID: 40870

Antibiotics Market

Published:
Report ID: 40728

Conjugation and Labeling Services Market

Published:
Report ID: 40756

Antiviral Drugs Market

Published:
Report ID: 40681

Intravitreal Injectable Market

Published:
Report ID: 7250

Pharmacogenomics Market

Published:
Report ID: 9486

Nosocomial Infection Treatment Market

Published:
Report ID: 14189

Anti-Cancer Drugs Market

Published:
Report ID: 39971

Vial Adaptors for Reconstitution Drug Market

Published:
Report ID: 15561

Congenital Disabilities Market

Published:
Report ID: 39845

Acquired Hemophilia Treatment Market

Published:
Report ID: 1124

Tyrosine Kinase Inhibitors (TKIs) Market

Published:
Report ID: 39696

Purchase Options

$2999
Delivery Format: Excel.
$4999
Designed for the individual purchaser.
$6999
Users located at a single corporate site or regional office.
$7999
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN